Investor Relations

Symbol
Nasdaq: STSS
Price
$
Volume
Change

Press Releases

Select Year:
Mon Feb 6, 2023 09:02 am

Sharps Technology Announces Closing of $3.8 Million Private Placement Priced At-the-Market

NEW YORK, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it c...
Wed Feb 1, 2023 09:20 am

Sharps Technology Announces Pricing of $3.8 Million Private Placement Priced at the Market

NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it e...
Tue Jan 31, 2023 08:00 am

Sharps Technology Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for Commercialization

First product shipped from Sharps' facility in Hungary and first to support the Nephron Pharmaceuticals distribution and sales collaboration Sharps anticipates 1.3 million units to be commercially available in February 2023 with additional shipments to follow and new products to be added ...
Tue Jan 10, 2023 08:00 am

Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023

High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based syringe products for the healthcare market NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “...
Tue Dec 20, 2022 08:00 am

Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products

Company now transitions from a pre-revenue research & development start-up to a revenue generating manufacturing company Shipments to commence by the end of the year to support the recently announced distribution and sales agreement with Nephron Pharmaceuticals and its European cust...